FLAM
ESPR

First Light Asset Management’s Esperion Therapeutics ESPR Stock Holding History

First Light Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-47,965
Closed -$1.13M – 67
2015
Q3 		$1.13M Buy
47,965
+28,035
+141% +$1.76M 0.56% 37
2015
Q2 		$1.63M Buy
+19,930
New +$1.95M 0.77% 36

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Light Asset Management's ESPR Position: Q4 2015 in Review

First Light Asset Management sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 47,965 shares — an estimated $1.13M sold.

First Light Asset Management first reported a position in ESPR in Q2 2015 and held it in 2 quarters. The position peaked at $1.63M in Q2 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • First Light Asset Management reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
  • First Light Asset Management sold 47,965 Esperion Therapeutics shares in Q4 2015, an estimated $1.13M.
  • First Light Asset Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 2 quarters.
  • First Light Asset Management's Esperion Therapeutics position peaked at $1.63M in Q2 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on First Light Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.